Plain Language Summaries

Scientific papers are usually written in a language full of technical terms which are not easy to understand for patients. Plain language summaries (PLS) explain the contents of such papers in an easy to understand manner.

 

List of some PLS

 

Danicopan:

Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis on Ravulizumab or Eculizumab Showed Hemoglobin Response Superiority With Add-on Danicopan vs Placebo

Danicopan as Add-On to Ravulizumab or Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: A Phase 3 Randomized Trial

 

Pegcetacoplan:

Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria:

 

Ravulizumab:

A suitable long-term treatment option for patients with paroxysmal nocturnal hemoglobinuria (2-year results)

Long-term ravulizumab treatment in complement inhibitor-experienced patients with PNH provides durable control of intravascular hemolysis with low incidence of major adverse vascular events and death

 

Non drug-specific

Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry

Patient Preferences and Quality of Life Implications of Ravulizumab (every 8 weeks) and Eculizumab (every 2 weeks) for the Treatment of Paroxysmal Nocturnal Hemoglobinuria